reports
Microbix Presents Novel HSV Test Control at EMMD
Microbix Presents Novel HSV Test Control at EMMD Innovative QAP to Support Patient Diagnosis & Analysis of Infected Tissue Samples MISSISSAUGA, Ontario, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of a novel Quality Assessment Product (“QAP™”) for supporting patient diagnosis and tissue analysis relating to infection with the Herpes Simplex Virus (“HSV”) at the European Meeting on Molecular Diagnostics (“EMMD”) taking place in Noordwijk, The ...
Microbix Achieves Essential EU Regulatory Accreditations
Microbix Achieves Essential EU Regulatory Accreditations IVDR Compliance and CE Certifications for REDx™ QAPs MISSISSAUGA, Ontario, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it has upgraded its European Union (“EU”) regulatory compliance for its diagnostic assay quality assessment products (“QAPs™”). Specifically, Microbix has obtained recognition of its quality management system compliance with the EU In Vitro Diagnostics Regulation (“IVDR”) and Conformité Europée...
Microbix Presenting at Muskoka Capital Conference
Microbix Presenting at Muskoka Capital Conference Meetings with Growth-Oriented Investors, September 27 to 29, 2024 MISSISSAUGA, Ontario, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to investors at the Muskoka Capital Conference, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, Ontario, September 27 to 29, 2024. Microbix’s CEO, Cameron Groome, will undertake a series of 18 one-on-one me...
Microbix Reports Continued Strong Results for Q3 Fiscal 2024
Microbix Reports Continued Strong Results for Q3 Fiscal 2024 Revenues of $5.1 million and Net Income of $0.25 million MISSISSAUGA, Ontario, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and first nine months of fiscal 2024 ended June 30, 2024 (“Q3” and “YTD”) with strong revenues, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients and devices businesses and resulting in material net income for Q3 and YTD...
Microbix Schedules Release of Results for Q3 Fiscal 2024
Microbix Schedules Release of Results for Q3 Fiscal 2024 Results Release and Webinar Discussion on Morning of August 14, 2024 MISSISSAUGA, Ontario, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements and management disclosure and analysis for its third quarter of fiscal 2024 ended June 30, 2024 (“Q3 2024”) prior to the start of trading on August 14, 2024. Furthermore, at 10:00 AM ET on that day, Microbix intends to hold a webinar d...
Microbix Presents HCV FLOQSwab® Format Test Control at ADLM
Microbix Presents HCV FLOQSwab® Format Test Control at ADLM Driven by Fingerstick Blood and Room-Temperature Stable for POCTs MISSISSAUGA, Canada, July 25, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of a novel Quality Assessment Product (“QAP™”) for supporting Point-of-Care-Tests (“POCTs”) for infection with the Hepatitis C Virus (“HCV”) at the American Diagnostic and Laboratory Medicine (“ADLM”) conference taking place in Chicago, Illinois July 29 t...
Microbix Hosts Minister Nina Tangri to Open Capacity Expansions
Microbix Hosts Minister Nina Tangri to Open Capacity Expansions Adds Product Development & QC Labs, Fully-Automated IVD Vial-Filling Capability MISSISSAUGA, Ontario, June 17, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces its hosting of Associate Minister of Small Business of Ontario, the Honourable Nina Tangri, to celebrate the opening of two expansions to its medical devices manufacturing capacity at one of its three adjacent Mississauga sites. Expansion one is a new 2,000 square ...
Microbix Advances Test-Ingredient Manufacturing Capabilities
Microbix Advances Test-Ingredient Manufacturing Capabilities Bioreactor Production of a Second Major Antigen – Increasing Capacity and Flexibility MISSISSAUGA, Ontario, June 04, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it has successfully adapted and extended the use of its bioreactor capabilities for production of another clinically and commercially-important test-ingredient (a native “Antigen”). This achievement will enhance production capacity for the referenced native ...
Microbix Reports Strong Results for Q2 Fiscal 2024
Microbix Reports Strong Results for Q2 Fiscal 2024 Revenues of $5.6 million and Net Income of $0.4 million MISSISSAUGA, Ontario, May 15, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2024 ended March 31, 2024 (“Q2” and “H1”), with strong growth in sequential and year-over-year quarterly revenues, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients and devices businesses and resulting in n...
Microbix Schedules Release of Results for Q2 Fiscal 2024
Microbix Schedules Release of Results for Q2 Fiscal 2024 Results Release and Webinar Discussion on Morning of May 15, 2024 MISSISSAUGA, Ontario, May 08, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements and management disclosure and analysis for its second quarter of fiscal 2024 ended March 31, 2024 (“Q2 2024”) prior to the start of trading on May 15, 2024. Furthermore, at 10:00 AM ET on that day, Microbix intends to hold a webinar dis...
Microbix Collaborator Introduces New Lab Accreditation Program
Microbix Collaborator Introduces New Lab Accreditation Program Microbix Product Supporting Testing for Drug-Resistant Sexually-Transmitted Infection MISSISSAUGA, Ontario, April 25, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that Labquality Ltd., a collaborator and customer, is presenting results of its use of Microbix Quality Assessment Products (“QAPs™”) for accreditation of clinical labs for conducting molecular (“MDx”) tests for antimicrobial-resistant (“AMR”) strains of M. ge...
Microbix Presenting at the 2024 Bloom Burton Conference
Microbix Presenting at the 2024 Bloom Burton Conference MISSISSAUGA, Ontario, April 11, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting at the Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Convention Center, North Building, on April 16 and 17, 2024. The Conference provides an opportunity to connect with Canadian, U.S., and international investors who are interested in the latest developments in...
Microbix Announces Annual and Special Meeting Voting Results
Microbix Announces Annual and Special Meeting Voting Results MISSISSAUGA, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF) (“Microbix®” or the Company”), a life sciences innovator and exporter, announces the voting results from the Annual and Special Meeting of Shareholders of the Company (the “Meeting”) which was held on March 27, 2024. At the Meeting, 42.64% of the issued and outstanding shares were represented. Shareholders voted in favour of all resolutions brought before the Meeting. Details of all resolutions that were voted upon are set...
Microbix’s Clot-Buster Drug Project Advances
Microbix’s Clot-Buster Drug Project Advances Sequel Pharma Executes Agreement with CDMO for Drug Substance Production MISSISSAUGA, Canada, March 14, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its funding and commercialization partner, Sequel Pharma, LLC (“Sequel”), has executed, with support from Microbix, an agreement with a leading international contract development and manufacturing organization (“CDMO”) for production of the active ingredient (i.e., “Drug Substance”) of ...
Microbix Unveils Test Controls for Head and Neck Cancer
Microbix Unveils Test Controls for Head and Neck Cancer HPV-related Tissue-Sample Mimics for QC of histology and PCR analyses MISSISSAUGA, Ontario, March 11, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of Quality Assessment Products (“QAPs™”) for supporting the quality control (“QC”) of histology and PCR-based tests driven by tissue-samples of Head and Neck cancer caused by human papilloma virus (“HPV”). Its results presentation will be made at EUROG...
Microbix Announces Issuance of Stock Options
Microbix Announces Issuance of Stock Options Using Shareholder-Approved Plan to Incentivize and Retain MISSISSAUGA, Ontario, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer and exporter, announces the issuance of stock options under its shareholder-approved 2018 stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers. Details of the Option Issuance In consultation with management, Microbix’s Board ...
Microbix Biosystems Inc: 1 director
A director at Microbix Biosystems Inc sold 72,500 shares at 0.390CAD and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Microbix Reports Record Results for Q1 Fiscal 2024
Microbix Reports Record Results for Q1 Fiscal 2024 Record Revenues of $8.4 million and Record Net Income of $2.5 million MISSISSAUGA, Ontario, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its first quarter of fiscal 2024 ended December 31, 2023 (“Q1”), with record quarterly revenues and a record quarterly profit, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients and devices, and material licensing revenues from its full...
Microbix Schedules Release of Results for Q1 Fiscal 2024
Microbix Schedules Release of Results for Q1 Fiscal 2024 Results Release and Webinar Discussion on Morning of February 14, 2024 MISSISSAUGA, Ontario, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements and management disclosure and analysis for its first quarter of fiscal 2024 ended December 31, 2023 prior to the start of trading on February 14, 2024. Furthermore, at 10:00 AM ET on that day, Microbix intends to hold a webinar disc...
Microbix Unveils Test Control for Gastric Ulcer Disease Pathogen
Microbix Unveils Test Control for Gastric Ulcer Disease Pathogen FLOQSwab-formatted QAP Supporting MDx Tests for H. pylori MISSISSAUGA, Ontario, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of a Quality Assessment Product (“QAP™”) for supporting the clinical use and accuracy of molecular (“MDx”) tests for infection with Helicobacter pylori (“H. pylori”), the bacterial cause of stomach ulcers, at Labquality Days, a lab diagnostics conference t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.